Amanote Research
Register
Sign In
The BCL2 Inhibitor Venetoclax Is Active in Non-Hodgkin Lymphoma
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2017-017
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
January 27, 2017
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Targeting BCL2 With Venetoclax Is a Promising Therapeutic Strategy for "Double-Protein-Expression" Lymphoma With MYC and BCL2 Rearrangements
Haematologica
Hematology
Non-Hodgkin Lymphoma
Characterization of a Novel Venetoclax Resistance Mutation (BCL2 Phe104Ile) Observed in Follicular Lymphoma
British Journal of Haematology
Hematology
Studies Identify Non-Hodgkin Lymphoma Suppressor
Cancer Discovery
Oncology
Anti-Tumor Activity of Selective Inhibitor of Nuclear Export (SINE) Compounds, Is Enhanced in Non-Hodgkin Lymphoma Through Combination With mTOR Inhibitor and Dexamethasone
Cancer Letters
Cancer Research
Oncology
MicroRNA Dysregulation in B-Cell Non-Hodgkin Lymphoma
Blood and Lymphatic Cancer: Targets and Therapy
Upfront Ahsct in Non Hodgkin Lymphoma-Better Outcome?
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Loss in McL-1 Function Sensitizes Non-Hodgkin’s Lymphoma Cell Lines to the BCL-2-selective Inhibitor Venetoclax (ABT-199)
Blood Cancer Journal
Oncology
Hematology
